The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of the first-in-class antimitochondrial metabolism agent CPI-613 in hematologic malignancies.
Timothy S. Pardee
Honoraria - Cornerstone Pharmaceuticals
Other Remuneration - Cornerstone Pharmaceuticals
Laura M DeFord-Watts
No relevant relationships to disclose
Erica Peronto
No relevant relationships to disclose
Denise A. Levitan
No relevant relationships to disclose
David Duane Hurd
No relevant relationships to disclose
Steven Kridel
No relevant relationships to disclose
Robin Harrelson
No relevant relationships to disclose
Megan Manuel
No relevant relationships to disclose
Susan Lyerly
No relevant relationships to disclose
Bayard L. Powell
No relevant relationships to disclose